Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Sallman

Showing results (1-10 of 162) with videos related to

Pageof 17
Sort By:
Haematologica|June 3, 2020
To target the untargetable: elucidation of synergy of APR-246 and azacitidine in <i>TP53</i> mutant myelodysplastic syndromes and acute myeloid leukemiaDavid A Sallman
Clinical Lymphoma, Myeloma & Leukemia|September 1, 2020
The Problem of TP53-Mutant MDS/AMLDavid A Sallman
Blood Advances|July 8, 2025
Can we harmonize classification of TP53 mutant MDS/AML?David A Sallman
British Journal of Haematology|August 2, 2021
Expanding the immune armoury against myelodysplastic syndromeDavid A Sallman, Somedeb Ball
Acta Haematologica|December 5, 2023
TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies, and Future ConsiderationsJeremy DiGennaro, David A Sallman
Clinical Lymphoma, Myeloma & Leukemia|August 23, 2015
Transformation of the Clinical Management of CMML Patients Through In-Depth Molecular CharacterizationDavid A Sallman, Eric Padron
Hemasphere|March 21, 2022
The role of innate immunity in MDS pathogenesisDavid A Sallman, Alan List
Hematology/Oncology and Stem Cell Therapy|May 18, 2016
Integrating mutation variant allele frequency into clinical practice in myeloid malignanciesDavid A Sallman, Eric Padron
Blood|January 24, 2019
The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromesDavid A Sallman, Alan List
Current Opinion in Hematology|December 2, 2021
Targeting the cluster of differentiation 47/signal-regulatory protein alpha axis in myeloid malignanciesChen Wang, David A Sallman
Pageof 17

Showing results (1-10 of 162) with videos related to

Sort By:
Pageof 17
Haematologica|June 3, 2020
To target the untargetable: elucidation of synergy of APR-246 and azacitidine in <i>TP53</i> mutant myelodysplastic syndromes and acute myeloid leukemiaDavid A Sallman
Clinical Lymphoma, Myeloma & Leukemia|September 1, 2020
The Problem of TP53-Mutant MDS/AMLDavid A Sallman
Blood Advances|July 8, 2025
Can we harmonize classification of TP53 mutant MDS/AML?David A Sallman
British Journal of Haematology|August 2, 2021
Expanding the immune armoury against myelodysplastic syndromeDavid A Sallman, Somedeb Ball
Acta Haematologica|December 5, 2023
TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies, and Future ConsiderationsJeremy DiGennaro, David A Sallman
Clinical Lymphoma, Myeloma & Leukemia|August 23, 2015
Transformation of the Clinical Management of CMML Patients Through In-Depth Molecular CharacterizationDavid A Sallman, Eric Padron
Hemasphere|March 21, 2022
The role of innate immunity in MDS pathogenesisDavid A Sallman, Alan List
Hematology/Oncology and Stem Cell Therapy|May 18, 2016
Integrating mutation variant allele frequency into clinical practice in myeloid malignanciesDavid A Sallman, Eric Padron
Blood|January 24, 2019
The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromesDavid A Sallman, Alan List
Current Opinion in Hematology|December 2, 2021
Targeting the cluster of differentiation 47/signal-regulatory protein alpha axis in myeloid malignanciesChen Wang, David A Sallman
Pageof 17